Engineered T cells for cancer treatment
- 1 June 2014
- journal article
- review article
- Published by Elsevier in Cytotherapy
- Vol. 16 (6) , 713-733
Abstract
No abstract availableKeywords
Funding Information
- (U.S. National Institutes of Health National Cancer Institute and National Heart, Lung and Blood Institute)
- V Foundation
- Dana Foundation
- James S. McDonnell Foundation
- Adrienne Helis Medical Research Foundation
This publication has 218 references indexed in Scilit:
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cellsGene Therapy, 2011
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in HumansTransplantation and Cellular Therapy, 2010
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safetyLeukemia, 2010
- An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell TherapiesStem Cells, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapyJournal of Immunological Methods, 2009
- Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7Molecular Therapy, 2009
- Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myelomaExperimental Hematology, 2008